autologous HIV-1 ApB DC vaccine

The autologous HIV-1 ApB DC vaccine is a therapeutic dendritic cell-based immunotherapy developed for the treatment of HIV-1 infection. The approach involves isolating monocyte-derived dendritic cells (DCs) from the patient and loading them ex vivo with apoptotic bodies derived from the patient's own HIV-1-infected cells. These antigen-loaded DCs are then re-administered to the patient to stimulate an immune response specifically targeting HIV-infected cells. The goal is to enhance virus-specific T-cell responses and reduce viral load, particularly during periods when antiretroviral therapy (ART) is interrupted. Clinical trials have demonstrated that this strategy is generally safe and immunogenic but has shown only modest effects on reducing viral set points after ART interruption[2][3][4][5]. The primary developer associated with clinical studies of this candidate is Sharon Riddler at University of Pittsburgh/NIAID.

Other names

autologous dendritic cell HIV-1 apoptotic body vaccineApB-DC vaccine